Amazon has been developing personalized vaccines for breast and skin cancers in conjunction with the Fred Hutchinson Cancer Center and has been recruiting patients to participate in an FDA-approved clinical trial for the shots, according to a public filing.
A summary of the project was first posted on Clinicaltrials.gov, an online database of clinical studies run by the U.S. National Library of Medicine, in October last year.
The study is titled “Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor-Positive Her2 Negative Metastatic Refractory Breast Cancer.”
According to a brief summary of the study, the Phase 1 clinical trial will look at the “safety of personalized neo-antigen peptide vaccine” in treating patients with melanoma or breast cancer that has spread to other places in the body or does not respond to treatment….